Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SugarPain

Financiado

Unravelling interactions between fermentable carbohydrates and the gut microbiot...

Unravelling interactions between fermentable carbohydrates and the gut microbiota in patients with IBS """What can I eat? This is the question that patients with irritable bowel syndrome (IBS) ask their general practitioner. Diet is the first line of treatment for IBS and is based on restricting foods containing a group of sugars (... ver más

30/04/2026

VLAAMS INSTITUUT...

192K€

Presupuesto del proyecto: 192K€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-08

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

191.76K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-113625RB-I00 SACRASA-ISOMALTASA Y OTRAS ENZIMAS QUE DIGIEREN CARBOHIDRATO... 259K€ Cerrado

PID2021-125695OA-I00 DIETA SIN GLUTEN EQUILIBRADA Y SEGURA: ESTUDIO DE BIOMARCADO... 120K€ Cerrado

AGL2016-75951-R ESTUDIO IN VITRO DE LA MICROBIOTA INTESTINAL DE INDIVIDUOS O... 115K€ Cerrado

AGL2010-16525 MECANISMOS DE INTERACCION ENTRE BIFIDOBACTERIAS Y SUS EXOPOL... 157K€ Cerrado

SAF2013-43677-R NEUROSFISIOLOGIA Y NEUROFISIOPATOLOGIA DIGESTIVA 254K€ Cerrado

RTI2018-093873-A-I00 REGULACION DE LA MICROBIOTA INTESTINAL A TRAVES DE MIRNAS DE... 145K€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2024-03-08
Fecha Fin: 2026-04-30

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 192K€

Descripción del proyecto """What can I eat? This is the question that patients with irritable bowel syndrome (IBS) ask their general practitioner. Diet is the first line of treatment for IBS and is based on restricting foods containing a group of sugars (Fermentable Oligo-, Di-, Mono-saccharides and polyol or FODMAPs), which are not fully absorbed by the host and fermented by the gut microbiota. Although effective, this treatment is not sustainable in the long term, as the diet requires limiting beneficial foods such as vegetables and fruits. To date, due to a lack of specific trials, our understanding of which and how specific FODMAPs contribute to IBS symptoms has yet to be uncovered. Based on (1) preliminary results showing a patient-specific response to purified FODMAPs in IBS patients, (2) the central role of the gut microbiota in FODMAP digestion and (3) the interindividual variation of the gut microbiota between individuals and IBS patients, I hypothesise that specific FODMAPs cause symptoms in IBS patients through individualised microbiome activity. By combining my bioinformatics skills and microbiome background with wet-lab microbiology expertise of the host group, I aim to identify bacterial species and metabolites causing the development of symptoms. Firstly, I will analyse samples and clinical data from a trial conducted in the host lab, in which patients were exposed to six purified FODMAPs, to identify microbiome changes in those experiencing symptoms. Next, I will test the interaction between FODMAPs and the identified microbes with high-throughput in-vitro fermentation, monitoring dynamic shifts in the gut microbial ecosystem and metabolic activity upon FODMAP exposure. Finally, I will determine if baseline microbiome or metabolite profiles can predict an individual's tolerance to specific FODMAPs. The outcomes of my research project will pave the way for innovative, effective, non-invasive, and personalised therapeutic approaches for a disorder affecting 10% of Europeans."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores